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The bone marrow tyrosine kinase in chromosome X (BMX) is pursued as a drug target because of its role
in various pathophysiological processes. We designed BMX covalent inhibitors with single-digit nanomolar
potency with unexploited topological pharmacophore patterns. Importantly, we reveal the first X-ray
crystal structure of covalently inhibited BMX at Cys496, which displays key interactions with Lys445,
responsible for hampering ATP catalysis and the DFG-out-like motif, typical of an inactive conformation.
Molecular dynamic simulations also showed this interaction for two ligand/BMX complexes. Kinome
selectivity profiling showed that the most potent compound is the strongest binder, displays intracellular
target engagement in BMX-transfected cells with two-digit nanomolar inhibitory potency, and leads to
BMX degradation PC3 in cells. The new inhibitors displayed anti-proliferative effects in androgen-receptor
positive prostate cancer cells that where further increased when combined with known inhibitors of
related signaling pathways, such as PI3K, AKT and Androgen Receptor. We expect these findings to guide
development of new selective BMX therapeutic approaches.
Introduction
Over recent years, the development of covalent kinase inhibitors
has gained more traction both in academia and pharmaceutical
industry.1–3 Historically, irreversible covalent inhibitors were
considered unsafe because of their lack of selectivity and con-
comitant undesired engagement of off-targets. However, these
potential liabilities can be overcome and the development of
covalent small molecule kinase inhibitors has recently seen
renewed interest. Irreversible covalent inhibitors can display
higher efficacy, since they achieve high target occupancy and a
prolonged pharmacodynamic effect, depending on the de novo
re-synthesis rate of the target protein.4,5 Supporting the value
and ‘‘renaissance’’ of covalent inhibitors, since October 2018 six
kinase-targeting small molecule covalent inhibitors6 were
approved by the FDA for clinical use: the EGFR inhibitors
Afatinibs, Neratinibs, Osimertinibs and Dacomitinibs and
the BTK inhibitors Ibrutinibs and Acalabrutinibs.7–11 However,
not all kinases are accessible for covalent binding since the
covalent bond formation depends on the nature and positioning
of the target amino acid.12–15 One such kinase of interest is the
epithelial and endothelial tyrosine kinase, commonly known as
bone marrow tyrosine kinase in chromosome X (BMX). BMX is a
major member of the TEC family of non-receptor tyrosine
kinases, together with ITK, TEC, BTK and TXK [reviewed in
ref. 16 and 17]. TEC kinases are activated by many cell-surface
receptor-associated signaling complexes and are recruited to the
plasma membrane or specific micro-environments by a variety
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of lipids and proteins. Through this mechanism, they are
involved in signal transduction in response to a myriad of
extracellular stimuli, including those mediated by growth-
factor receptors, cytokine receptors, G-protein coupled receptors,
antigen-receptors, integrins and death receptors. Moreover, TEC
kinases regulate many of the major signaling pathways, such as
those of PI3K, PKC, PLCg, AKT, STAT3 and p21-activated kinase
1 (PAK1)18,19 and are responsible for a variety of cell processes,
including regulation of gene expression, calcium mobilization,
actin reorganization/motility and survival/apoptosis.16,17
BMX is widely expressed in granulocytes, monocytes, cells of
epithelial and endothelial lineages, as well as brain, prostate,
lung and heart.19–22 It is specifically involved in tumorigenicity,
adhesion, motility, angiogenesis, proliferation and differentia-
tion. Moreover, it has been found to be overexpressed in
numerous cancer types, such as breast,23–25 prostate,26,27
colon28 and cervical carcinoma,29 which suggests that elevated
levels of BMX increase cancer-cell survival. BMX is also required
for stem-cell maintenance and survival22 and its up-regulation
provides a survival benefit to both primary tumors and cancer
stem cells that are highly resistant to apoptosis and many
chemotherapeutic agents.
Homozygous BMX knockout mice have a normal life span
without any obvious altered phenotype, which suggests that
therapies based on BMX inhibition might have few side
effects30 and although BMX is a key regulator it might not
represent a fundamental effector. Therefore, by considering the
existence of multiple downstream target proteins, the integra-
tion in multiple and diverse signaling pathways, and the fact
that it regulates proliferation, migration and has an anti-
apoptotic effect, BMX emerges as a potential target for multiple
aspects of cancer therapy. Recent studies also highlighted that
modulation of BMX activity sensitizes cells to therapeutic
agents to improve response to chemotherapy DNA damaging
agents or radiation. These studies show strong evidence that
both direct inhibition of BMX and modulation of related path-
ways result in increased therapeutic efficacy.28,31,32
BMX-IN-1 is one of the most potent BMX inhibitors (IC50:
8.0 nM) reported in the literature, which also binds to BTK with
very high affinity (IC50: 10.4 nM).
33 Like other BMX covalent
inhibitors, it reacts with a cysteine residue (Cys496) in the ATP
binding site. This residue is a unique occurrence found in the
ATP binding pocket and is present in all five members of the
TEC family kinase members. Therefore, by virtue of structural
homology these compounds could also be covalent inhibitors
of the other kinases in the TEC family.
In this study, we describe the discovery of JS24–JS27, which
are among the most potent covalent inhibitors of BMX reported
to date and possess topological pharmacophoric features not
exploited in the BMX inhibitors’ chemical space. We asserted
the selectivity against a panel of 36 kinases that possess an
equally placed cysteine or up- and downstream regulators of
the BMX signaling pathway. We further demonstrated that the
lead compounds have the potential to inhibit proliferation of
androgen-receptor-positive prostate-cancer cells (LNCaP) and
their inhibitory potential is enhanced in a co-treatment
regimen with known PI3K, AKT and androgen receptor inhibi-
tors (LY294002, AKT1/2 and Flutamide, respectively). As part of
our efforts to explore this scaffold to identify regions of the
molecule amenable to conjugation we also report the first X-ray
structure of BMX with a covalent inhibitor as well as MD
simulations on two complexes with this receptor, which provide
insight into the mode of binding and will contribute towards
the future development of inhibitors with improved efficacy
and selectivity.
Results and discussion
Discovery of a single-digit nanomolar BMX inhibitor
To evaluate substituent tolerability at each position and to
establish an optimal vector through positioning of different
functionalities, a structure–activity relationship (SAR) study was
used to establish the limitations of the tool chemotype BMX-IN-1.
A total of 24 analogues were synthesized in an attempt to both
enhance potency and optimize physicochemical properties
within the allowable SAR study (Fig. S1, ESI†). Upon systematic
evaluation, we found that analogues with substituents in posi-
tion R3 (Fig. 1a) of the quinoline moiety had only marginal
effects on BMX inhibition Furthermore, any change of the
electrophilic warhead (position R1, Fig. 1a) for cysteine covalent
ligation resulted in loss of potency as illustrated for instance by
Fig. 1 Compound structures and biochemical characterization of their
inhibitory effects on BMX and BTK. (a) The structures of BMX-IN-1, the SAR
explored (shown in Fig. S1, ESI†) and JS24–JS27 leads generated in this
study. (b) Eurofins DiscoverX in vitro BMX activity evaluation by measuring
the phosphorylation of a biotinylated peptide with human recombinant
enzyme expressed in insect cells and HTRF detection method, tested in
duplicate, showing mean  S.D. Cells were treated for 1 h and IC50 values
were calculated and plotted by using GraphPad Prism 8 based on a
sigmoidal dose response curve. (c) Eurofins DiscoverX in vitro BTK activity
evaluation by measuring scintillation count with a radiometric assay tested
in duplicate, showing mean  S.D. Cells were treated for 1 h and IC50
values were calculated and plotted by using GraphPad Prism 8 based on a
sigmoidal dose response curve. (d) Projection of BMX and BTK inhibitor
space with a multidimensional scaling algorithm. Green: BTK inhibitors;
orange: BMX inhibitors; grey: BMX-IN-1; red: JS24–J27.
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the introduction of the enamide substituents in JS10 and JS11
(Fig. S1, ESI†). The substituents in the aromatic ring bearing
the amide functionality play an unexpected relevant role for the
activity, affording different reactivity patterns arising from non-
covalent interactions. Introducing a strong electron-donating
group such as a methoxy group (OMe) (JS9E) in R2 decreases
potency by 4-fold. In contrast, the use of a weak electron-
donating group, such as a methyl substituent, has different
effects depending on the positioning. Thus, moving the methyl
group to the ortho position abolishes target inhibition (JS9C),
while a methyl positioning in the meta position slightly
improved inhibition by 2-fold. Even more striking is the effect
of no substituent in the ring (JS9D), which increased inhibition
by 6-fold. Since the electronic influence of the methyl substi-
tuents in the different positions is not expected to account for
these differences, we consider that a conformational effect may
play an important role. The ortho substitution may increase the
constraints for fitting into the pocket, while the removal of the
methyl groups affords less spatial restriction.
Interestingly, substituents in position R4 (Fig. 1a and Fig. S2,
ESI†) were found to significantly enhance BMX inhibition
relative to BMX-IN-1 (Fig. 1a and Fig. S2, ESI†). With this SAR
information in hand, we decided to prepare JS24–JS27 that were
designed to include substituents at position R4 of the quinoline
and incorporated features from previous analogues that
afforded a preferred overall profile, varying methyl positioning
in R2 and retaining the acrylamide electrophilic warhead for
cysteine covalent binding. Details for the synthesis of JS24–JS27
can be found in the ESI† (Schemes S1–S4). Compound JS24,
which features a methyl sulfonamide at position 7, showed
considerable gain of inhibition potency from IC50 50 to 7.5 nM
relative to the parent molecule BMX-IN-1 (Fig. 1a and b).
Further derivatives that presented changes in the aniline core
(R2) with a methyl in the meta position (JS25) and without any
substituent in this position (JS26), but that features the same
methyl sulfonamide at R4, were designed and prepared. Both
compounds showed significantly improved activity (IC50 of 3.5
and 9.1 nM, respectively; Fig. 1a and 1b).
Similarly, in JS27 we installed a substituted piperazine in the
R4 position that affords less restraint relative to the aromatic
phenyl-sulfonamide ring, but which renders it the least active
analogue of the series (13.7 nM) albeit considerably more
potent (E4-fold) relative to BMX-IN-1 (Fig. 1a and b).
Modulation of physicochemical profile, BTK inhibition and
pharmacophore diversity
Taking into account that BMX-IN-1 does not exhibit an optimal
physicochemical profile, we aimed at lowering the lipophilicity
and increasing water solubility within the established SAR. Initial
investigations showed an improved profile when the sulfonamide
aromatic ring was replaced by cyclic aliphatic amines (Table S1,
ESI†). These observations prompted us to use 1-(methylsulfonyl)-
piperazine in compound JS27. Consequently, we were able to
obtain the analogue with the best in silico lipophilicity and water
solubility profile (c log P = 2.32 and log S = 4.36; Table S1, ESI†).
Interestingly, compound JS26 shows a slightly improved reduction
of c log P. The presence of a methyl group (compounds JS24
and JS25) increases hydrophobicity and, consequently, removal
of this group (JS26–JS27) decreases the hydrophobicity and the
partition coefficient.
We anticipated that some analogues could have limited
membrane permeability, which is of utmost importance for
any drug, in particular if a molecule is targeting cytoplasmic
proteins. For assessment of drug permeability, we relied on
parallel artificial membrane permeability assay (PAMPA) per-
formed at Pion Inc. with the PAMPA Evolutiont instrument
(Table S1, ESI†). We observed that compounds JS24 (6.8 
106 cm s1) and JS25 (3.8  106 cm s1) show a lower PAMPA
permeability relative to BMX-IN-1 (8.9  106 cm s1), whereas
compounds with the unsubstituted backbone aniline (JS26
and JS27) show increased permeability (19  106 cm s1 and
12  106 cm s1, respectively). As shown in Fig. 1a, the four
leads share a similar scaffold and only compound JS27 displays
a distinct structural feature. Because other analogues display
similar c log P values with improved PAMPA permeability (up to
45  106 cm s1; Table S1, ESI†), the observed increased
permeability may be mostly a result of intramolecular inter-
actions, such as hydrogen bonding, more than the lipophilic
contribution, because the algorithm for c log P calculation does
not consider 3D conformations. In addition, we measured particle
sizes by using dynamic light scattering (DLS). Up to 95% of false
positive readouts in high-throughput screens originate from
colloidal aggregation.34 This phenomenon is driven by the
physicochemical properties of the small molecule and buffer
conditions. Generally, aggregates bind non-specifically to pro-
teins, sequestering and denaturating them. Our data shows that,
regardless of their limited solubility, compounds JS24–JS27 do
not form aggregates at the relevant inhibitory concentrations,
which rules out unspecific binding to BMX (Table S1, ESI†).
To date, all the reported BMX inhibitors also display the
ability to inhibit Bruton’s tyrosine kinase (BTK). To determine
if our leads were selective binders of BMX, we evaluated
inhibitory capacity of our compounds against BTK. For the
BTK IC50 assay (KinaseProfiler by Eurofins DiscoverX), we
selected BMX-IN-1, the two analogues with higher BMX inhibi-
tory capacity (JS24 and JS25) and JS27, which presents the best
in silico physicochemical profile, and also offers the possibility
of derivatization. The results showed that all the leads are also
potent BTK inhibitors, in the low nanomolar range (Fig. 1c).
The same inhibitory trend is observed with an increase of 62-, 33-
and 15-fold potency gain with JS25, JS24 and JS27, respectively,
relative to BMX-IN-1. Interestingly, in this assay BMX-IN-1 dis-
plays 7-fold higher IC50 against BTK than BMX.
We aimed to modulate the physicochemical properties of the
molecules to enhance the overall ‘‘drug-likeness’’ profile of the
ligands. Ligand efficiency (LE) and lipophilic efficiency (LipE)
are two important metrics that are associated with improved
prospects for good drug properties (e.g. bioavailability) and are
used as criteria for progression of the most promising candi-
dates across drug discovery pipelines.35 LE is used to compare
binding efficacy of inhibitors/ligands relative to their size, and
LipE is used to compare binding efficacy by taking into
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consideration the lipophilicity of the molecules. With regards
to BMX inhibition, compound JS27 displayed a major
LipE improvement relative to BMX-IN-1 (5.54 versus 3.36)
empowered by the drastic reduction in c log P as a result
of the introduction of the aliphatic sulfonamide. Analogues
JS24–JS26 displayed mild LipE improvement (4.17, 4.43 and
4.45), which is mainly due to their structural similarity with
BMX-IN-1. However, the LE improvement is mostly driven by
the increased potency of all analogues rather than a decrease in
the molecules’ size (Table 1). Similarly, the designed ligands
offer a greater improvement of LE and LipE metrics with
respect to BTK binding, relative to BMX-IN-1, driven also by a
drastic potency gain.
Finally, we analyzed the pharmacophore diversity of the
designed ligands against that of known BMX and BTK inhibitors.
Ligand data was collected from ChEMBL v24, pre-processed as
previously described36 and projected to the plane by means of a
learning algorithm (Fig. 1d). It is apparent that BTK has been
more often interrogated with small molecules (green) and that
the studied chemotypes are more diverse in regard to topological
pharmacophore arrangements relative to previously described
BMX modulators (blue). Compounds JS24–JS27 (yellow) focus on
unexplored regions in BMX inhibitor space but overlaps with
previously studied BTK chemotypes. Indeed, our compounds
have shown potent activities against BTK, which is fully in line
with the output of the learning algorithm. Altogether, our data
shows that compounds JS24–JS27 explore a new chemical
space and provides a rationale to re-investigate and potentially
repurpose BTK inhibitors as leads for future development of
BMX ligands and vice versa.
JS24–JS27 show strong binding interactions with BMX
We further characterized the binding interaction between
JS24–JS27 and BMX by using differential scanning fluorimetry
(DSF) and surface plasmon resonance (SPR). Purified recombi-
nant human BMX protein (hBMX) was first subjected to thermal
scanning in the absence and presence of JS24–JS27, and the
respective protein melting temperature (Tm) calculated. As
shown in Table 2, BMX-IN-1 increases the Tm value by
8.04 1C. Among the lead inhibitors, JS24 displayed the highest
stabilization, with an increase in Tm of 11.34 1C. Compounds
JS27 (10.81 1C), JS26 (9.34 1C) and JS25 (9.30 1C) showed high
stabilization of the protein, which also suggests direct binding
to BMX with a higher affinity relative to parent scaffold BMX-
IN-1 (Table 2 and Table S2, ESI†). The binding of JS24–JS27 to
BMX immobilized surfaces was then monitored in real-time by
SPR assays (Table 2 and Fig. S3, Table S3, ESI†). BMX-IN-1 was
shown to bind to BMX with an affinity of KD = 69 nM. It is
important to note that it was not possible to accurately fit the
dissociation rate constant of BMX-IN-1 interaction with BMX
because of the initial non-covalent binding event. In contrast,
JS24–JS27 KD values could not be determined due to the even
higher prolonged off-rates, which were outside the range of the
instrument specifications. The results suggest that compounds
JS24–JS27 have higher affinity interactions with BMX, showing
comparable association rates (kon from 5.4  104–1.4 
105 M1s1) but, most importantly, very slow dissociation rates
(koff o 1  104 s1), which is in agreement with the covalent
nature of the interaction (Table 2).
JS24–JS27 displays greater irreversible binding efficacy relative
to BMX-IN-1
The inactivation of BMX occurs in a two-step process that is
governed by two parameters: the affinity of the initial non-
covalent binding, KI, and the rate of the subsequent covalent
bond-forming reaction with the thiol of the cysteine residue,
kinact. The rate of inactivation (kinact/KI) is a second-order event,
which describes the efficiency of covalent bond formation,.37
Therefore, we evaluated the irreversible binding efficiency of
our rationally designed compounds, as previously described.38
The kinetic analysis presented in Table 3, reveals that com-
pound JS25 exhibits the best binding fit with the target, with an
inhibition rate constant of 323 pM. This represents an increase
in excess of 10-fold relative to BMX-IN-1 (KI: 4.07 nM). The other
leads display a similar binding affinity among themselves
(1.93–2.52 nM), lower than JS25 and approximately 2-fold
higher than BMX-IN-1. However, the rate of covalent bond
formation of the bound inhibitor (determined by kinact) shows
that compounds JS24, JS25, and JS26 showed slightly improved
efficiency (0.335, 0.378 and 0.443 min1, respectively) in com-
parison to BMX-IN-1 (0.217 min1) and JS27 (0.166 min1).
Consequently, the irreversible binding efficiency of JS25
Table 1 Ligand efficiency and lipophilic efficiency of BMX-IN-1 and
JS24–JS27 against BMX and BTK
Compound LE (BMX) LipE (BMX) LE (BTK) LipE (BTK)
BMX-IN-1 0.26 3.36 0.23 2.50
JS24 0.29 4.17 0.29 4.00
JS25 0.30 4.43 0.30 4.22
JS26 0.30 4.45 Nd Nd
JS27 0.30 5.54 0.29 5.29
LE – ligand efficiency; LipE – lipophilic efficiency; Nd – not defined.
Table 2 Melting temperature (Tm) shift calculated with a DSF assay and kinetic constants calculated from SPR
Compound Aveg. Tm (1C) apo-BMX Tm (1C) DTm (1C) kon/M
1 s1 koff/s
1 KD/M
BMX-IN-1 60.17  0.32 52.13  0.11 8.04  0.32 7.4  103 5.10  104 6.9  108
JS24 63.57  0.01 52.23  0.06 11.34  0.01 1.4  105 o1  104 Nda
JS25 61.43  0.48 52.13  0.11 9.30  0.48 5.4  104 o1  104 Nda
JS26 61.47  0.21 52.13  0.11 9.34  0.21 7.2  104 o1  104 Nda
JS27 62.94  0.06 52.13  0.11 10.81  0.06 9.9  104 o1  104 Nda
Nd – not determined. a KD not measured due to very prolonged off-rates (outside instrument specifications).
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(19.4 mM1 s1) is the highest of the series, whereas BMX-IN-1
shows the lowest result (0.89 mM1 s1) relative to the remaining
inhibitors. Overall, these results provide quantitative evidence
that the improved activity is mostly driven by changes in the
binding complementarity between the compound and target
rather than faster rate of covalent binding. Thus, taking into
account that all the analogues have the same Michael acceptor
moiety, the enhanced activity must be a result of the structural
modifications introduced in the scaffold.
JS24 covalently modifies cysteine 496 in BMX
Mass spectrometry (MS) studies confirmed the covalent bind-
ing of JS24 at cysteine 496 of BMX. The truncated hBMX was
analyzed by native MS and the protein mass found was 30899
Da (Fig. 2a). The protein was then treated with 2.5 mM of JS24
at room temperature for 30 min in PBS pH 7.4 and directly
analyzed by denaturing MS. The protein was fully denatured
and cleaned on a reverse phase column, discarding any non-
specific binding, to retain only any covalently linked com-
pound. The mass found upon incubation with JS24 is 31 424
Da, which is 525 Da larger than the apo-form of hBMX (Fig. 2b).
This result suggests covalent conjugation of a single molecule
of JS24 to hBMX. Furthermore, MS/MS analysis after digestion
of the drug conjugated hBMX indicates the covalent modifica-
tion at cysteine residue 496 (Fig. 2c).
The first X-ray structure of BMX with covalent inhibitor
To characterize the inhibition mechanism and binding mode
of JS24 to BMX at the atomic level, we tested a variety of
commercial crystallization screens to obtain a protein crystal
suitable for X-ray diffraction. Crystals were grown through
co-crystallization of BMX protein at a final concentration of
10 mg mL1, with a 2-fold molar excess concentration of
inhibitor JS24, in a lead condition that consists of 0.2 M
imidazole-malate buffer, pH 5.5, and 42% v/v PEG 600. The
X-ray crystal structure of BMX in complex with inhibitor JS24
was determined at 2.0 Å resolution (PDB ID: 6I99) with a well-
defined electron density map around the BMX ATP binding
pocket in which the inhibitor is bound (Fig. 3a). The values of
the equivalent isotropic atomic displacement parameters for the
ligand atoms within the pocket are comparable to those of the
protein atoms they are interacting with, an indication of full
ligand occupancy of the binding site. Not surprisingly, an increase
is observed in the sulfonamide aromatic ring because this group
is more exposed to the solvent and hence more mobile.
The crystal structure shows the expected covalent binding
between the acrylamide warhead and Cys496. Other major
interactions of the inhibitor with the enzyme active site are
mediated through hydrogen bonds between the nitrogen in
the quinoline ring and Ile492, and between the Lys445 and the
oxygen located in the fused pyridinone ring (Fig. 3b). The
hydrogen bond between JS24 and Lys445 is actually one of
the key points to regulate BMX activity. The conserved b3 Lys
interacts with aC-helix Glu residue to form a salt bridge
required for ATP catalysis. The binding of JS24 to Lys445 alters
this interaction between the b3 Lys and the aC-helix Glu and
consequently inactivates BMX. The aromatic rings of JS24 are
engaged in CH/p interactions with the side chains of Tyr491,
Ala443, Val431, and Leu543 (Fig. S4, ESI†). Compound JS24 is
further stabilized by a hydrogen bond between a water molecule
(W1) and the carbonyl oxygen of the acrylamide group. A second
water molecule (W2) stabilizes the first (W1) through a hydrogen
bond, and forms hydrogen bonds with the peptide nitrogen of
Cys496 and the terminal amide group of Asn499 (Fig. 3b).
The crystal structure also shows that the DFG-motif adopts
an out-like conformation (Fig. 3c) in which the Asp554 side
chain is positioned in the back cleft, away from the ATP
binding pocket, and the Phe555 aromatic ring points up into
the gatekeeper region blocking the b3 Lys445-aC Glu460 ion
pair formation. Both the activation loop and the DFG-out-like
conformation are similar to what is observed in the only
reported BMX crystal structure with non-covalent inhibitors
Dasatinib and PP2.39 The positioning of the BMX DFG-motif is
reminiscent of an inactive conformation or DFG-out, typically
found in BTK and other kinases inactive structures,40 and it is
also commonly observed in type II inhibitor complexes.41 In the
apo-BTK (PDB: 3P08), the DFG-in Asp539 rotates towards the
ATP binding pocket to chelate magnesium and the DFG-in
Phe540 is positioned in the back cleft to allow the formation
of the b Lys430-aC Glu445 ion pair, which is important for
catalysis. In BMX/JS24 complex the DFG-out-like Asp554 points
down and away from the ATP binding pocket and the Phe555
swings up to block the ion pair formation (Fig. 3d). However,
relative to the DFG-out-like structure in BMX/JS24 complex with
a BTK DFG-out structure (PDB: 3PIY), both structures display
complete rotation of the DFG-aspartate residue away from the
Table 3 Determination of the kinetic parameters KI, kinact, kinact/KI
a
Compound KI [nM] kinact [min
1] kinact/KI [mM
1 s1]
JS25 0.32  0.05 0.378  0.034 19.4  1.55
JS26 1.93  0.18 0.443  0.003 3.86  0.34
JS24 2.52  0.01 0.335  0.001 2.22  0.01
JS27 2.15  0.13 0.166  0.003 1.29  0.10
BMX-IN-1 4.07  0.06 0.217  0.005 0.89  0.20b
a Results tested in duplicate, showing mean  S.D. b Value with a 0.06
mM1 s1 deviation from published results.38
Fig. 2 Mass spectrometric analysis of BMX and JS24 conjugated to BMX.
(a) Native MS analysis of hBMX. The measured molecular weight is
indicated. (b) Denaturing MS analysis of drug-conjugated hBMX. The
measured molecular weight is indicated. (c) Tandem MS analysis of the
drug conjugated tryptic peptide of hBMX labelled on the sequence (top)
and MS/MS mass spectrum (bottom). The red asterisk indicates the Cys site
to which JS24 is covalently linked.
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ATP binding pocket. Only the BTK DFG-out Phe540 residue
rotates away from the core of the protein and towards the ATP
binding pocket to create a back pocket capable of accepting an
aromatic moiety (Fig. 3e).
Finally, the positioning of the sulfonamide aromatic ring is
also of utmost importance. This group does not interact with
any important residue and it is in fact pointing out of the ATP
pocket (Fig. S4, ESI†). Interestingly, this feature would allow for
the installation of a linker or chemical handle in this region
of the molecule without altering significantly the inhibitor
binding capacity of the lead compound.
Molecular dynamics (MD) simulations on BMX covalently
linked to JS24 and JS27
We performed then 0.5 ms MD simulations on BMX covalently
linked to JS24 (Fig. 4a and b). Computational details can be
Fig. 3 Crystal structure of the BMX-JS24 complex (a). Representation of the co-crystal structure of BMX catalytic domain in complex with JS24 (PDB
code 6I99). The panel shows the well-defined electron density around the inhibitor, which is bound to BMX ATP binding pocket through a covalent bond
with a cysteine residue (Cys496). (b) Non-bonding interactions of JS24 in the ATP binding pocket. (c) BMX DFG-motif adopting the out-like
conformation. (d) Analysis of the BMX-DFGout-like motif conformation and BTK DFGin. (e) Analysis of the BMX DFGout-like conformation with BTK DFGout.
Paper RSC Chemical Biology
This journal is©The Royal Society of Chemistry 2020 RSC Chem. Biol., 2020, 1, 251--262 | 257
found in the ESI.† According to these calculations, the binding
mode found in the X-ray structure is retained in solution. Both
hydrogen bonds releveled by the crystallographic studies, one
between the backbone of Ile492 and the nitrogen atom of the
quinoline and the other one between the side chain of Lys445 and
the carbonyl oxygen of the quinoline ring, are populated in the
complex (Fig. 4c). Also, as it occurs in the X-ray structure, JS24 is
engaged in CH/p interactions with the side chains of Val431,
Ala443, Tyr491 and Leu543 (Fig. S5, ESI†). The MD calculations
show that the DFG-motif also adopts an out-like conformation in
solution (Fig. 4a). Thus, Phe555 precludes the ion pair formation
between Lys445 and Glu460, which is supported by the distance
between the side chains of Lys455 and Glu460 (Fig. 4d). Asp554
side chain is located away from the ATP binding pocket (Fig. 4a).
The good agreement between the X-ray and the structure proposed
by the simulations prompted us to propose a 3D-model for BMX
linked to ligand JS27. To this purpose, JS27 covalently linked to
Cys496 was superimpose on the X-ray structure of the BMX/JS24
complex. and used as starting structure in the simulations. The
simulations show that JS27 adopts a similar pose in the binding
site than JS24 (Fig. 4b). Thus, JS27 is engaged in the same hydrogen
bonds with the receptor as in BMX/JS24 complex, with populations
close to 61.0% and 34.6% for the interactions involving Lys445 and
Ile492, respectively. The aromatic system of the ligand interacts
with the hydrophobic residues Val431, Ala443, Tyr491 and Leu543
through hydrophobic interactions (Fig. S5, ESI†). As in BMX/JS24
complex, the binding of JS27 impedes the ion pair Lys445-Gl460
formation (Fig. 4d). Significantly, in both complexes, the sulfona-
mide group of the ligands does not stablish any contact with the
receptor and is exposed to the solvent.
JS25 is a selective TEC family inhibitor
Most of BMX inhibitors reported to date offer poor selectivity
because they are both BMX and BTK inhibitors. Their cellular
effect is often attributed to off-target activity either upstream or
downstream of BMX signaling pathways. To investigate in
which targets the new inhibitors could have an effect we tested
potent inhibitor JS25 against a panel of 36 BMX-related kinases
in the Eurofins DiscoverX’s KINOMEscant platform at a
concentration of 1 mM.
It is important to note that from the extensive number of
accessible cysteine residues distributed across the whole
kinome not all are available for covalent modification.12–14
BMX belongs to a restricted group that includes 10 other
kinases that share an equivalently placed cysteine in the ATP
binding pocket. This group comprises members from the TEC
family (BTK, ITK, TXK and TEC), the EGFR family (EGFR, Her2,
Her4), JAK3, BLK and dual specificity mitogen-activated protein
kinase 7 (MAP2K7). Therefore, we included the whole TEC,
EGFR and JAK family in our screening, and the Src family and
Lkb1, which also have a cysteine within the same sequence
alignment. We also included kinases involved in upstream (Src,
FAK, PI3K, mTOR, PDK1) and downstream (Akt, PAK1, TAM)
regulation of BMX signaling pathway and non-receptor tyrosine
protein kinase Abl. The KinomeScan platform is a binding
assay and the screening showed that JS25 displays a strong
binding affinity against all the members of TEC family that
share an equivalently placed cysteine and within these, higher
affinity is observed towards BMX, BTK and TEC (Table 4).
As stated above, the TEC family has high sequence similarity
and in particular residues in the ATP binding kinase domain
share 40–65% identity and 60–80% similarity. The ATP binding
sites are also highly conserved between the TEC and Src
families with 14 identical residues out of 18 that comprise
the ATP binding pocket. More specifically, BMX shares a 57%
similarity to Src and most importantly, one of the key determi-
nants of kinase selectivity – the gatekeeper residue – is a Thr in
both the Src family and the TEC family members except ITK.39
It is therefore not surprising that JS25 also binds Blk (and JAK3)
whereas no affinity was observed with other potential targets.
Fig. 4 (a and b) Structural ensembles derived from 0.5 ms MD simulations on BMX covalently linked to JS24 and JS27. (c) Population of the most relevant
hydrogen bonds between the ligands and BMX derived from the MD simulations. (d) Evolution of the Lys445–Glu460 distance along the MD simulations
of both complexes. See also Videos 1 and 2 (ESI†). JS24, JS27, Lys445, Glu460, Asp554 and Phe555 are shown as sticks. The protein is shown as ribbons
and only the first conformer (time = 0 ns) is shown for clarity.
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These results reveal JS25 as a selective probe for TEC kinases
and suggest that any cellular activity mediated by JS25 is
probably a result of inhibition of any of the TEC kinases rather
than any off-target inhibition of upstream and downstream
BMX regulators.
Intracellular BMX inhibition and degradation by JS25
To validate target affinity and identification for JS25, we per-
formed an intracellular target engagement kinase assay with
HEK293 cells expressing NanoLucs-BMX fusion vector with
Promega’s NanoBRETt TE Intracellular Kinase Assay. The cell
proliferation depends on BMX kinase activity that was used to
monitor the cellular activity of the compounds (IC50). As shown
in Fig. 5a, the IC50 determination showed the inhibitory capa-
city of JS25 (IC50: 44.8 nM) is 10 times greater than BMX-IN-1
(IC50: 495 nM), which aligns with the previous observations of
an increased biochemical potency with similar activity
difference. We next investigated whether the treatment of
wild-type PC3 cells with JS25, as well as BMX-IN-1 (as a control),
would induce degradation of BMX. After 24 and 72 h, it was
possible to verify that the level of expressed BMX protein in PC3
cells decreased upon treatment with JS25 as well as with the
control molecule (Fig. 5b and Fig. S11, ESI†). This data
indicates that JS25 is able both inhibit catalytic activity and
degrade BMX it in cells.
Cancer cell growth inhibition by BMX inhibitors
The role of BMX in different pathologies is not yet fully validated.
Nevertheless, it has been implicated in many regulatory
mechanisms and despite the absence of a BMX dependent
disease model, prostate cancer cell lines have been used to
evaluate anti-proliferative effects of the inhibitors in a cellular
context. In a previous experiment (unpublished results) we
screened several inhibitors from Table S1 (ESI†) in a collection
of cell lines representing prostate, brain, blood, breast, ovary,
lung, bone marrow and lymphoid tumour tissues. Compounds
were incubated with cells for 72 h in a 386 well-plate format to
monitor dose-dependent impact on viable cell growth by using
the CellTiter-Glos luminescent assay, which quantifies ATP and
the presence of metabolically active cells. The study included
JS24, BMX-IN-1 and the structurally similar compounds JS10
and JS11 which do not bind to BMX (Fig. S1 and Table S1, ESI†).
The results presented in Table 5 show that JS10 and JS11
(non-binders) have little or no effect on viable cell growth of the
majority of the tested cell lines. BMX-IN-1 demonstrated more
potent inhibitory effects relative to JS24 in the four prostate
cancer cell lines that were included in the panel, 22RV1, PC3,
LNCaP and DU145, particularly in those dependent on androgen
receptor signaling (LNCaP and 22RV1). In contrast, androgen
receptor negative cells (DU145 and PC3) were overall more
resistant to treatment. In addition, JS24 showed potent inhibitory
effects against LNCaP and 22RV1 but also against PC3,
which are androgen receptor negative cells. Furthermore, both
compounds were also potent inhibitors of viable cell growth for
Table 4 Kinase selectivity of JS25 over 36 BMX-related kinases in the KINOMEscant platform. The results for primary screen binding interactions at
1 mM concentration are reported as % DMSO control
Family Target % Ctrl Family Target % Ctrl
TEC BMX 1.3 Src FYN 99
BTK 0 SRC 92
ITK 4.7 YES1 85
TEC 0.4 BLK 16
TXK 3.4 FGR 93
EGFR EGFR 87 LCK 80
ERBB2 89 HCK 95
ERBB3 91 LYN 100
ERBB4 66 mTOR MTOR 100
JAK JAK1(JH1domain-catalytic) 93 Liver Kinase B1 STK11 52
JAK2(JH1domain-catalytic) 81 Pkb AKT1 100
JAK3(JH1domain-catalytic) 21 AKT2 94
TYK2(JH1domain-catalytic) 100 AKT3 99
FAK PTK2 93 PAK1 PAK1 100
PI3K PIK3CA 79 TAM AXL 93
PIK3CB 89 MERTK 89
PIK3CG 64 Abl ABL1-phosphorylated 100
PIK3CD 100 PDPK1 PDPK1 92
Fig. 5 (a) Intracellular target engagement in HEK293 cells transiently
transfected with BMX expressing NanoLucs-BMX fusion vector with
Promega’s NanoBRETt TE Intracellular Kinase Assay. Assay performed at
Reaction Biology Corporation (USA), with concentrations tested in dupli-
cate, showing mean  S.D. Cells were treated for 1 h and IC50 values were
calculated and plotted by using GraphPad Prism 8 based on a sigmoidal
dose response curve. (b) JS25 (10 mM) and BMX-IN-1 (10 mM) induce
degradation of wild-type BMX in PC3 cells. Sampling was taken after 24 h
and 72 h of incubation with JS25 and BMX-IN-1. Band intensity was
measured using ImageJ and normalized with a-Tubulin band intensity.
Differences between groups were revealed through 2way-ANOVA. Data
are mean  standard deviation obtained from at least three independent
measurements (n = 3). See ESI† for additional data and analysis.
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RS4 (11) (lymphoblast) and DAUDI (T-lymphoblast) cells, in
which BTK is highly overexpressed. Altogether, these results
demonstrate BMX inhibition impacts viable cell growth of
prostate cancer cells and prompted us to investigate further
the importance of the androgen receptor and related BMX
pathways in these cell lines.
Androgen-receptor positive prostate-cancer cells are sensitive to
JS24–JS27
Based on the results showed in the previous section, we tested
the ability of compounds JS24–JS27 to inhibit the proliferation
of LNCaP and PC3 prostate cancer cell lines by using CellTiter-
Glows. The androgen-receptor negative PC3 cells are resistant
to the treatment, with no significant anti-proliferative effect at
the maximum concentration tested (10 mM). With androgen-
receptor positive cells LNCaP a different profile was observed.
BMX-IN-1 and JS24 showed a GI50 of 1.7 and 1.5 mM, respec-
tively. Compound JS27 was the least active (GI50 9.3 mM), and
JS25 and JS26 inhibited proliferation with a GI50 of 6.6 and
7.7 mM, respectively, as shown in Fig. 6.
To determine whether the growth inhibition was due to
apoptosis, we carried out fluorescence-assisted cell sorting
analysis with propidium iodide staining. LNCaP cells were
incubated with BMX-IN-1 and JS24–JS27 for 64h, at 10 mM
and results showed that no marked differences in the percen-
tage of necrotic events relative to the vehicle control, which
suggests that in these conditions these molecules do not
enhance cell death (Fig. S6, ESI†). It is not surprising that all
these compounds show only moderate proliferation inhibitory
potential in prostate-cancer cell lines and it remains questionable
whether modulation of BMX per se is relevant or not, towards anti-
proliferative effects.33 In fact, a large body of evidence in the
literature shows that selective or dual BMX/BTK inhibitors have
poor anti-proliferative effects in BMX-dependent models, most
probably from dynamic compensation of signaling mechanisms.
Focus has been placed on the modulation of BMX activity to
sensitize prostate-cancer cells to other therapeutic agents because
anti-proliferative effects are only observed in combination with
inhibitors of related pathways.42 BMX-IN-1 growth inhibition of
RV-1 cells could only be potentiated with the Akt inhibitor
MK2206;33 ABT-737, a non-covalent inhibitor only induces
apoptosis upon co-treatment with PI3K inhibitors;28 the dual
BMX/BTK inhibitor CTN06 requires co-treatment with autophagy
inhibitor chloroquine (CQ) or docetaxel to inhibit PC3 cells
growth43 and a similar profile is observed with the dual BMX/
Src inhibitor CTA095 to synergize with CQ and paclitaxel.44
The activation of BMX in response to PI3K signaling is just
one of the mechanisms through which the levels of BMX become
increased in prostate cancer.43,45 A very recent study46 showed
that BMX expression in prostate cancer is suppressed directly
through androgen receptor as a result of binding to BMX.
Consequently, BMX expression rapidly increases in response to
androgen deprivation therapy which enhances tyrosine kinase
signaling and the subsequent emergence of castration-resistant
Table 5 Viable cell growth inhibition of compounds BMX-IN-1, JS10, JS11 and JS24 in a panel of prostate, brain, blood, breast, ovary, lung and
lymphoid cancer cellsa
Tissue Cell line BMX-IN-1 JS24 JS10 JS11
Prostate LNCaP 1.81  0.05 4.4  NC 9.7  NC 10.41  NC
22 RV1 2.07  0.06 6.66  0.09 4.86  0.11 7.3  NC
PC3 10.98  1.13 4.8  NC ND 20.12  NC
DU145 17.7  NC ND ND ND
Brain U-87MG 5.33  0.19 5.04  0.01 ND ND
SK-N-MC 2.36  NC 8.53  0.44 11.19  NC 8.24  NC
Blood Jurkat 5.99  NC 5.48  ND 9.71  1.48 6.36  0.17
Kasumi 3.13  0.06 5.12  0.12 4.37  0.04 10.14  0.07
Breast MDA-MB-231 23.61  0.48 ND ND ND
Ovary CAOV3 7.68  0.13 8.56  NC 17.30  NC 19.31  NC
OVCAR3 ND ND ND ND
Bone marrow H1299 ND 7.28  0.37 19.42  NC ND
Lung RS4(11) 1.176  0.06 2.09  NC 5.06  NC 6.66  NC
Lymphoid DAUDI 1.68  0.07 1.27  0.05 2.57  0.09 4.57  0.12
a Viable cell growth was measured after 72 h incubation in 386 well-plate format. GI50 values were tested in triplicate and are reported as the mean
 SD in mM. ND, non-determined, no growth inhibition observed within the concentrations tested. NC, non-calculated. When ambiguous fit was
observed curves were top (100%) and bottom (0%) constrained and GI50 was determined with 4-P least squares fit. In these cases, SD is not
calculated by GraphPad Prism 8.
Fig. 6 Anti-proliferative activity of compounds BMX-IN-1 and JS24–
JS27 against LNCaP (a) and PC3 (b) prostate-cancer cell lines. Briefly,
proliferation in LNCaP and PC3 cells was measured after 96 h incubation,
in 96-well plates with BMX-IN-1 and JS24–JS27. GI50 values are reported
in mM and are the mean of three individual experiments performed in
triplicate. N.d., non-determined, no growth inhibition observed within the
concentrations tested.
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prostate cancer. This study further highlights the potential use
of BMX inhibitors in combination therapy, in this case in
combination with AR targeting. To further validate this hypo-
thesis and assess the effect of our inhibitors with other drugs,
we performed a co-treatment regimen with known inhibitors of
related upstream and downstream pathways.
Co-treatment of LNCaP cells with JS24–JS26 and androgen
receptor antagonist, PI3K and AKT inhibitors
As shown above, BMX inhibition alone induces limited cell death
in BMX-expressed cell lines owing to the existence of compensatory
mechanisms in signaling pathways. To evaluate whether our BMX
inhibitors could potentially be used in combination treatment
regimens, we sought to look at the synergistic anti-proliferative
effects of BMX inhibitors when combined with other therapeutic
agents, which pre-sensitize prostate cancer cells. For this purpose,
LNCaP cells were co-treated in a combinatorial fashion with
compounds JS24–26, AKT1/2 (AKT inhibitor), Flutamide (androgen
receptor antagonist) and LY294002 (PI3K inhibitor). Cell viability
was evaluated after 5 days with CellTiter-Glos and compared with
the overall anti-proliferative effects of the compounds alone. An
optimization study was performed by screening several concentra-
tions (Fig. S7, ESI†) to determine the ideal conditions to obtain
initial viability above 80% with the individual inhibitors alone
(Fig. S8, ESI†). Based on these results, we tested JS24 (at 3 mM),
JS25 (5 mM) and JS26 (6 mM) with AKT1/2 (1 mM), Flutamide (50 mM)
and LY294002 (3 mM). Results are shown in Fig. 7.
Although the control concentrations of JS24–26 and the
inhibitors did not have an effect on reducing cell viability upon
co-treatment, a marked viability decrease was observed in all
tested conditions. With AKT1/2 a decrease in cell viability
ranging from 48% (with JS24) to 63% (with JS26) was observed,
relative to control AKT1/2. With Flutamide, the most effective
combination was with compound JS25 (63% cell viability
reduction) and the least effective with JS24 (44% reduction).
Finally, co-treatment with LY294002 decreased cell viability by
35% (with JS24 and JS26) and 59% (with JS25). Overall, these
results demonstrate a synergistic effect between JS24-26 and
AKT1/2, Flutamide and LY294002 in cancer cell proliferation
capable of overcoming the compensatory mechanisms of BMX
inhibition, and open the possibility of becoming useful mole-
cules for drug combination approaches.
Conclusions
We explored a chemical scaffold that contains an archetypal
tricyclic core of a quinoline with a fused pyridinone, which is
present in BMX covalent inhibitor BMX-IN-1. We sought to intro-
duce a chemical handle that may be used for further derivatization
whilst simultaneously tuning the physicochemical properties. We
found that rational modification introduced at the position 7 of the
quinoline moiety leads to potent, single-digit nanomolar inhibition
of BMX and BTK. Topological pharmacophoric features are outside
the chemical space previously explored in BMX inhibition, and
afford molecules with more favorable physicochemical profiles
with a reduced c log P and increased permeability (JS26 and JS27).
We also unveiled the X-ray crystal structure of BMX with a covalent
inhibitor (JS24), which shows the protein with the ‘‘DFG-out like’’
motif typical of an inactive conformation. The crystal structure also
shows that the ‘‘tail substituent’’, opposite to the acrylamide war-
head points outside the ATP pocket, which suggests an exit vector
for further derivatizations. A comparable pose for ligands JS24 and
JS27 were proposed by extensive MD simulations performed on the
complexes with BMX.
We determined the rate of covalent modification and, to our
knowledge, this is the highest value reported in the literature.
The kinetic analysis showed that this is mostly driven from the
potency of the first reversible binding event (KI = 323 pM) and
shows that our rational design afforded a preferred fit for the
BMX binding pocket. In a cellular context, most potent com-
pound JS25 also showed low nanomolar potency in a target
engagement assay (45 nM) in BMX-dependent cells (transfected
HEK293) which is 10-fold superior to the reference ligand.
Treatment of PC3 cells with JS25 also led to degradation BMX.
Furthermore, all lead compounds displayed anti-proliferative
effects in androgen-receptor positive prostate cancer cells that
where further increased when combined with known inhibitors
of related signaling pathways, further highlighting the potential
of combinatorial effects with BMX-related pathways.
As stated above, selectivity among members of the TEC
family is hard to achieve. Interestingly, available data shows
that therapeutically active drugs are not selective molecules.
Fig. 7 Anti-proliferative activity in LNCaP cells of compounds JS24–JS26
in combination with AKT1/2 (AKT inhibitor), Flutamide (androgen receptor
antagonist) and LY293002 (PI3K inhibitor). (a) Cells co-treated with JS24
(3 mM), JS25 (5 mM) and JS26 (6 mM) with AKT1/2 (1 mM); (b) JS24 (3 mM), JS25
(5 mM) and JS26 (6 mM) with Flutamide (50 mM); (c) JS24 (3 mM), JS25 (5 mM)
and JS26 (6 mM) with LY294002 (3 mM). Values are reported in % cell viability
normalized to DMSO controls and are the mean of three individual experi-
ments performed in triplicate. Determined P-values are illustrated as ns (P 4
0.05), * (P r 0.05), ** (P r 0.01), *** (P r 0.001) and **** (P r 0.0001).
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Ibrutinib, developed as a covalent BTK inhibitor, has been
approved by the FDA for the treatment of chronic lymphocytic
leukemia, mantle cell leukemia (MCL) and Waldenström
macroglobulinemia and is currently in multiple clinical trials
because it has proved efficacy in different indications, such as
non-small cell lung cancer and autoimmune diseases.7,47,48
With a broad selectivity profile, Ibrutinib inhibits the whole
TEC family, EGFR, JAK3, Her2, Blk and Itk kinases. Acalabrutinib,
a second generation BTK inhibitor that was also granted FDA
approval for MCL is more selective, and only inhibits BTK, TEC,
BMX and TXK.49 Other BTK inhibitors in clinical development
(Spebrutinib, Zanubrutinib and Tirabrutinib) also display a broad
selectivity for kinases with a cysteine as the Cys496 residue in
BMX,50 consequently, it is reasonable to extrapolate that the
compounds developed here can become therapeutically useful
as BMX inhibitors and find application in other TEC-related B-cell
malignancies. The most potent compound JS25 also has a multi-
target profile and is active against all five TEC kinases, JAK3 and
BLK. As such, we are currently evaluating the utility of these new
molecules in B-cell related lymphocytic diseases where TEC-
kinases play a prominent role.17,51
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Ciência e Technologic/Ministério da Educação e Ciência,
through national funds and co-funded by FEDER under the
PT2020 Partnership Agreement, and MOSTMICRO (project
LISBOA-01-0145-FEDER-007660) co-funded by FCT/MCTES
and FEDER funds through COMPETE2020—Programa Opera-
cional Competitividade e Internacionalização (POCI) are also
acknowledged. The authors thank Dr Vikki Cantrill for her help
with the preparation and editing of this manuscript.
Notes and references
1 J. Singh, R. C. Petter, T. A. Baillie and A. Whitty, Nat. Rev.
Drug Discovery, 2011, 10, 307–317.
2 Z. Zhao and P. E. Bourne, Drug Discovery Today, 2018, 23,
727–735.
3 A. Chaikuad, P. Koch, S. A. Laufer and S. Knapp, Angew.
Chem., Int. Ed., 2018, 57, 4372–4385.
4 T. Barf and A. Kaptein, J. Med. Chem., 2012, 55, 6243–6262.
5 R. Lagoutte, R. Patouret and N. Winssinger, Curr. Opin.
Chem. Biol., 2017, 39, 54–63.
6 A. Abdeldayem, Y. S. Raouf, S. N. Constantinescu, R. Moriggl
and P. T. Gunning, Chem. Soc. Rev., 2020, 49, 2617–2687.
7 L. A. Honigberg, A. M. Smith, M. Sirisawad, E. Verner,
D. Loury, B. Chang, S. Li, Z. Pan, D. H. Thamm,
R. A. Miller and J. J. Buggy, Proc. Natl. Acad. Sci. U. S. A.,
2010, 107, 13075–13080.
8 J. C. Byrd, B. Harrington, S. O’Brien, J. A. Jones, A. Schuh,
S. Devereux, J. Chaves, W. G. Wierda, F. T. Awan, J. R. Brown,
P. Hillmen, D. M. Stephens, P. Ghia, J. C. Barrientos, J. M. Pagel,
J. Woyach, D. Johnson, J. Huang, X. Wang, A. Kaptein,
B. J. Lannutti, T. Covey, M. Fardis, J. McGreivy, A. Hamdy,
W. Rothbaum, R. Izumi, T. G. Diacovo, A. J. Johnson and
R. R. Furman, N. Engl. J. Med., 2015, 374, 323–332.
9 V. A. Miller, V. Hirsh, J. Cadranel, Y. M. Chen, K. Park,
S. W. Kim, C. Zhou, W. C. Su, M. Wang, Y. Sun, D. S. Heo,
L. Crino, E. H. Tan, T. Y. Chao, M. Shahidi, X. J. Cong,
R. M. Lorence and J. C. Yang, Lancet Oncol., 2012, 13,
528–538.
10 J.-C. Soria, Y. Ohe, J. Vansteenkiste, T. Reungwetwattana,
B. Chewaskulyong, K. H. Lee, A. Dechaphunkul, F. Imamura,
N. Nogami, T. Kurata, I. Okamoto, C. Zhou, B. C. Cho,
Y. Cheng, E. K. Cho, P. J. Voon, D. Planchard, W.-C. Su,
J. E. Gray, S.-M. Lee, R. Hodge, M. Marotti, Y. Rukazenkov
and S. S. Ramalingam, N. Engl. J. Med., 2017, 378, 113–125.
11 S. K. Rabindran, C. M. Discafani, E. C. Rosfjord, M. Baxter,
M. B. Floyd, J. Golas, W. A. Hallett, B. D. Johnson,
R. Nilakantan, E. Overbeek, M. F. Reich, R. Shen, X. Shi,
H.-R. Tsou, Y.-F. Wang and A. Wissner, Cancer Res., 2004,
64, 3958–3965.
12 J. Zhang, P. L. Yang and N. S. Gray, Nat. Rev. Cancer, 2009, 9,
28–39.
13 Q. Liu, Y. Sabnis, Z. Zhao, T. Zhang, S. J. Buhrlage, L. H. Jones
and N. S. Gray, Chem. Biol., 2013, 20, 146–159.
14 Z. Zhao, Q. Liu, S. Bliven, L. Xie and P. E. Bourne, J. Med.
Chem., 2017, 60, 2879–2889.
15 B. R. Lanning, L. R. Whitby, M. M. Dix, J. Douhan,
A. M. Gilbert, E. C. Hett, T. O. Johnson, C. Joslyn,
RSC Chemical Biology Paper
262 | RSC Chem. Biol., 2020, 1, 251--262 This journal is©The Royal Society of Chemistry 2020
J. C. Kath, S. Niessen, L. R. Roberts, M. E. Schnute, C. Wang,
J. J. Hulce, B. Wei, L. O. Whiteley, M. M. Hayward and
B. F. Cravatt, Nat. Chem. Biol., 2014, 10, 760–767.
16 C. I. Smith, T. C. Islam, P. T. Mattsson, A. J. Mohamed,
B. F. Nore and M. Vihinen, BioEssays, 2001, 23, 436–446.
17 N. J. Horwood, A. M. Urbaniak and L. Danks, Int. Rev.
Immunol., 2012, 31, 87–103.
18 J. S. Jarboe, S. Dutta, S. E. Velu and C. D. Willey, Recent Pat.
Anticancer Drug Discovery, 2013, 8, 228–238.
19 Y. Qiu and H. J. Kung, Oncogene, 2000, 19, 5651–5661.
20 X. Wen, H. H. Lin, H. M. Shih, H. J. Kung and D. K. Ann,
J. Biol. Chem., 1999, 274, 38204–38210.
21 O. A. Guryanova, Q. Wu, L. Cheng, J. D. Lathia, Z. Huang,
J. Yang, J. MacSwords, C. E. Eyler, R. E. McLendon,
J. M. Heddleston, W. Shou, D. Hambardzumyan, J. Lee,
A. B. Hjelmeland, A. E. Sloan, M. Bredel, G. R. Stark,
J. N. Rich and S. Bao, Cancer Cell, 2011, 19, 498–511.
22 J. Kaukonen, I. Lahtinen, S. Laine, K. Alitalo and A. Palotie,
Br. J. Haematol., 1996, 94, 455–460.
23 R. Bagheri-Yarmand, M. Mandal, A. H. Taludker,
R. A. Wang, R. K. Vadlamudi, H. J. Kung and R. Kumar,
J. Biol. Chem., 2001, 276, 29403–29409.
24 K. Y. Chen, L. M. Huang, H. J. Kung, D. K. Ann and
H. M. Shih, Oncogene, 2004, 23, 1854–1862.
25 I. Cohen, M. Maoz, H. Turm, S. Grisaru-Granovsky, B. Maly,
B. Uziely, E. Weiss, R. Abramovitch, E. Gross, O. Barzilay,
Y. Qiu and R. Bar-Shavit, PLoS One, 2010, 5, e11135.
26 B. Dai, H. Chen, S. Guo, X. Yang, D. E. Linn, F. Sun, W. Li,
Z. Guo, K. Xu, O. Kim, X. Kong, J. Melamed, S. Qiu and
Y. Qiu, Cancer Res., 2010, 70, 5587–5596.
27 B. Dai, O. Kim, Y. Xie, Z. Guo, K. Xu, B. Wang, X. Kong,
J. Melamed, H. Chen, C. J. Bieberich, A. D. Borowsky,
H. J. Kung, G. Wei, M. C. Ostrowski, A. Brodie and Y. Qiu,
Cancer Res., 2006, 66, 8058–8064.
28 D. S. Potter, P. Kelly, O. Denneny, V. Juvin, L. R. Stephens,
C. Dive and C. J. Morrow, Neoplasia, 2014, 16, 147–157.
29 Y. Li, N. Cui, P. S. Zheng and W. T. Yang, Oncotarget, 2017, 8,
49238–49252.
30 I. Rajantie, N. Ekman, K. Iljin, E. Arighi, Y. Gunji,
J. Kaukonen, A. Palotie, M. Dewerchin, P. Carmeliet and
K. Alitalo, Mol. Cell. Biol., 2001, 21, 4647–4655.
31 D. S. Potter, M. Galvin, S. Brown, A. Lallo, C. L. Hodgkinson,
F. Blackhall, C. J. Morrow and C. Dive, Mol. Cancer Ther.,
2016, 15, 1248–1260.
32 J. L. Fox and A. Storey, Cancer Res., 2015, 75, 1345–1355.
33 F. Liu, X. Zhang, E. Weisberg, S. Chen, W. Hur, H. Wu,
Z. Zhao, W. Wang, M. Mao, C. Cai, N. I. Simon, T. Sanda,
J. Wang, A. T. Look, J. D. Griffin, S. P. Balk, Q. Liu and
N. S. Gray, ACS Chem. Biol., 2013, 8, 1423–1428.
34 D. Reker, G. J. L. Bernardes and T. Rodrigues, Nat. Chem.,
2019, 11, 402–418.
35 M. M. Hann and G. M. Keserü, Nat. Rev. Drug Discovery,
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